Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature

被引:0
|
作者
Raj Kumar Shrimali
Peter Denzil Correa
Nick S. Reed
机构
[1] Beatson West of Scotland Cancer Centre,Department of Clinical Oncology
[2] University of Glasgow,Beatson West of Scotland Cancer Centre, Gartnavel General Hospital
来源
Medical Oncology | 2011年 / 28卷
关键词
Small cell cancer; Ovary; Chemotherapy; Surgery;
D O I
暂无
中图分类号
学科分类号
摘要
Small cell carcinomas of the ovary (SCCO) are rare and aggressive malignant neoplasms carrying a poor prognosis. Although multi-modality treatment including chemotherapy leads to a high initial response rate, the majority of these patients relapse quickly and die within 2 years of diagnosis. Because these tumours are rare, there is no consensus to support any particular approach to management. We present 2 cases and review the relevant literature to make a number of recommendations. The treatment of these unusual cases should to be individually discussed in a multi-disciplinary team and multi-modality treatment including surgery, chemotherapy and radiotherapy should be considered for patients with limited disease. Conservative, fertility-preserving surgery may be considered in younger women with early-stage disease. Induction chemotherapy with weekly dose-dense and dose-intense carboplatin and taxane is useful. Prophylactic cranial irradiation (PCI) may be considered in patients in remission after primary treatment with chemotherapy or surgery.
引用
收藏
页码:766 / 770
页数:4
相关论文
共 50 条
  • [1] Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature
    Shrimali, Raj Kumar
    Correa, Peter Denzil
    Reed, Nick S.
    MEDICAL ONCOLOGY, 2011, 28 (03) : 766 - 770
  • [2] Weekly dose-dense chemotherapy for ovarian cancer
    Tanday, Sanjay
    LANCET ONCOLOGY, 2016, 17 (04): : E138 - E138
  • [3] Dose-dense chemotherapy in advanced ovarian cancer
    Bookman, Michael A.
    LANCET, 2009, 374 (9698): : 1303 - 1305
  • [4] Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
    Petty, W. Jeffrey
    Laudadio, Jennifer
    Brautnick, Lynsay
    Lovato, James
    Dotson, Travis
    Streer, Nathan P.
    Weaver, Kathryn E.
    Miller, Antonius A.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (06) : 2057 - 2063
  • [5] Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature
    Reinisch, Mattea
    Ataseven, Beyhan
    Kuemmel, Sherko
    BREAST CARE, 2016, 11 (01) : 13 - 20
  • [6] Controversies on the treatment of ovarian cancer with dose-dense chemotherapy
    Suarez-Zaizar, Alberto
    Cardenas-Cardenas, Eduardo
    Araceli Barajas-Castro, Yadira
    Cortes-Esteban, Patricia
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [7] Dose-dense/dose-intense ABVD in high-risk Hodgkin's lymphoma
    Russo, F.
    Corazzelli, G.
    Frigeri, F.
    Marcacci, G.
    Pinto, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 135 - 136
  • [8] Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC.
    Waller, L. L.
    Miller, A. A.
    Streer, N. P.
    Lovato, J. F.
    Petty, W. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Dose-intense and dose-dense regimens in Hodgkin lymphoma and aggressive non-Hodgkin Lymphoma
    Kahl, Brad
    CLINICAL LYMPHOMA & MYELOMA, 2007, 8 : S42 - S42
  • [10] Dose-Dense Chemotherapy for Breast Cancer
    Bayraktar, Soley
    Arun, Banu
    BREAST JOURNAL, 2012, 18 (03): : 261 - 266